US EditionIndependent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
Summary by stocktitan.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
bioAffinity Technologies (NASDAQ: BIAF) announced the release of a white paper by Dr. Gordon Downie highlighting the real-world impact of CyPath® Lung, their noninvasive sputum-based test for early-stage lung cancer detection. The paper details four clinical cases where CyPath® Lung significantly influenced decision-making for patients with indeterminate pulmonary nodules.Dr. Downie, Director of the Lung Nodule Clinic at Titus Regional Medical C…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
